Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $78.97
  • 50 Day Moving Average: $79.45
  • 200 Day Moving Average: $85.72
  • 52-Week Range: $76.67 - $111.11
  • Trailing P/E Ratio: 6.93
  • Foreward P/E Ratio: 6.84
  • P/E Growth: -32.10
  • Market Cap: $104.21B
  • Outstanding Shares: 1,319,658,000
  • Beta: 1.06
Profitability:
  • Net Margins: 50.50%
  • Return on Equity: 106.75%
  • Return on Assets: 35.82%
Debt:
  • Debt-to-Equity Ratio: 1.36%
  • Current Ratio: 1.76%
  • Quick Ratio: 1.58%
Additional Links:
Companies Related to Gilead Sciences:

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 10 Hold Ratings, 17 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.68)
Consensus Price Target: $105.04 (33.02% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$80.00View Rating Details
9/27/2016Leerink SwannDowngradeOutperform -> Market Perform$112.00 -> $94.00View Rating Details
9/25/2016Bank of America Corp.Reiterated RatingNeutral$100.00View Rating Details
9/23/2016GabelliReiterated RatingBuyView Rating Details
9/22/2016Piper Jaffray Cos.Set Price TargetBuy$108.00View Rating Details
9/22/2016Jefferies GroupReiterated RatingBuy$91.00View Rating Details
9/22/2016Berenberg BankInitiated CoverageBuyView Rating Details
9/14/2016Credit Suisse Group AGLower Price TargetOutperform$115.00 -> $95.00View Rating Details
9/6/2016Morgan StanleySet Price TargetHold$100.00View Rating Details
8/11/2016RBC Capital MarketsSet Price TargetBuy$105.00View Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00View Rating Details
7/28/2016Barclays PLCReiterated RatingOverweightView Rating Details
7/27/2016Maxim GroupSet Price TargetHold$88.55View Rating Details
7/27/2016BMO Capital MarketsReiterated RatingMarket Perform$97.00 -> $98.00View Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details
7/26/2016Robert W. BairdReiterated RatingOutperform$135.00 -> $122.00View Rating Details
7/26/2016Needham & Company LLCDowngradeBuy -> Hold$84.60 -> $88.55View Rating Details
7/26/2016Royal Bank Of CanadaLower Price TargetOutperform$120.00 -> $105.00View Rating Details
7/5/2016Cowen and CompanyReiterated RatingOutperform$125.00View Rating Details
5/31/2016Citigroup Inc.Reiterated RatingBuy$105.00View Rating Details
5/14/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00View Rating Details
4/10/2016MizuhoReiterated RatingBuy$130.00View Rating Details
2/5/2016Evercore ISIReiterated RatingBuy$115.00View Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details
2/1/2016William BlairReiterated RatingOutperformView Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details
8/7/2015Stifel NicolausDowngradeHoldView Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00View Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details
2/27/2015NomuraSet Price TargetBuy$141.00View Rating Details
10/31/2014Edward JonesInitiated CoverageHoldView Rating Details
10/13/2014FBR & CoBoost Price TargetOutperform$125.00 -> $130.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2016        
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
Current Year EPS Consensus Estimate: $11.76 EPS
Next Year EPS Consensus Estimate: $11.55 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20162$3.03$3.25$3.14
Q3 20164$2.79$3.04$2.92
Q4 20163$2.82$2.98$2.88
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Annual Dividend:$1.88
Dividend Yield:2.38%
Payout Ratio:16.56% (Based on Trailing 12 Months of Earnings)
15.99% (Based on Current Year Consensus EPS Estimate)
16.28% (Based on Next Year Consensus EPS Estimate)

Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 77.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline
thecountrycaller.com logoGilead Sciences, Inc. (GILD) Signs Five-Year Partnership With WHO (NASDAQ:GILD)
www.thecountrycaller.com - September 28 at 5:00 PM
smarteranalyst.com logoCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. (GILD) and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration (NASDAQ:GILD)
www.smarteranalyst.com - September 28 at 5:00 PM
News IconIs Gilead Sciences Inc. (NASDAQ:GILD), a large market cap stock a smart buy? (NASDAQ:GILD)
twincountynews.com - September 28 at 5:00 PM
fool.com logoGilead Sciences Stock Downgraded: 3 Things You Need to Know (NASDAQ:GILD)
www.fool.com - September 28 at 2:51 PM
smarteranalyst.com logoMerrill Lynch Weighs in on Biotech Giants Gilead Sciences, Inc. (GILD) and Pfizer Inc. (PFE) - Smarter Analyst (NASDAQ:GILD)
www.smarteranalyst.com - September 28 at 10:05 AM
thecountrycaller.com logoHere's Why Gilead Sciences, Inc. (GILD) Stock is Trading in the Red Today (NASDAQ:GILD)
www.thecountrycaller.com - September 27 at 5:14 PM
seekingalpha.com logoAllergan Validates Gilead Sciences NASH Pipeline (NASDAQ:GILD)
seekingalpha.com - September 27 at 5:14 PM
News IconTop Gainers of the Day: Gilead Sciences Inc. (NASDAQ:GILD) from Biotechnology (NASDAQ:GILD)
twincountynews.com - September 27 at 5:14 PM
smarteranalyst.com logoMerrill Lynch Weighs in on Biotech Giants Gilead Sciences, Inc. (GILD) and Pfizer Inc. (PFE) (NASDAQ:GILD)
www.smarteranalyst.com - September 27 at 5:14 PM
News IconGilead Sciences, Inc (GILD) Stock Is Significantly Undervalued (NASDAQ:GILD)
amigobulls.com - September 27 at 5:14 PM
investors.com logoGilead 'Paralyzed' On Likely Hepatitis C Share Loss To AbbVie, Merck (NASDAQ:GILD)
www.investors.com - September 27 at 5:13 PM
publicnow.com logoGilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration (NASDAQ:GILD)
www.publicnow.com - September 27 at 5:13 PM
forbes.com logoNotable Tuesday Option Activity: GILD, LGND, NHI (NASDAQ:GILD)
www.forbes.com - September 27 at 4:27 PM
seekingalpha.com logoGilead: Ways To Unlock Shareholder Value - Seeking Alpha (NASDAQ:GILD)
seekingalpha.com - September 27 at 9:47 AM
finance.yahoo.com logoAnalysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More (NASDAQ:GILD)
finance.yahoo.com - September 27 at 9:47 AM
thestreet.com logoGilead (GILD) Stock Falls on Ratings Downgrade (NASDAQ:GILD)
www.thestreet.com - September 27 at 9:47 AM
thecountrycaller.com logoFitzroy Data Boosts R&D At Gilead Sciences, Inc. (GILD) – Leerink (NASDAQ:GILD)
www.thecountrycaller.com - September 26 at 5:21 PM
forbes.com logoWho's Doing What To Whom In The Back Seat Of The Car? (NASDAQ:GILD)
www.forbes.com - September 26 at 5:21 PM
thestreet.com logoWall Street Sells Off on Worries Over Clinton-Trump Showdown (NASDAQ:GILD)
www.thestreet.com - September 26 at 5:21 PM
seekingalpha.com logoGilead: Ways To Unlock Shareholder Value (NASDAQ:GILD)
seekingalpha.com - September 26 at 9:55 AM
marketrealist.com logoHow Gilead Dominates the HCV Space (NASDAQ:GILD)
marketrealist.com - September 26 at 9:55 AM
stocksdaily.net logoGilead Sciences, Inc. (NASDAQ:GILD) Had $14607 In Cash And Short-Term Investments (NASDAQ:GILD)
www.stocksdaily.net - September 25 at 4:45 PM
smarteranalyst.com logoGilead Sciences, Inc. (GILD) Remains Top Pick: Piper Jaffray - Smarter Analyst (NASDAQ:GILD)
www.smarteranalyst.com - September 24 at 9:47 AM
smarteranalyst.com logoMerrill Lynch Remains Cautious on Gilead Sciences, Inc. (GILD); Here's Why - Smarter Analyst (NASDAQ:GILD)
www.smarteranalyst.com - September 24 at 9:47 AM
thestreet.com logoCramer: Here Are the Reasons the Market Is Hated (NASDAQ:GILD)
realmoney.thestreet.com - September 24 at 9:47 AM
smarteranalyst.com logoMerrill Lynch Remains Cautious on Gilead Sciences, Inc. (GILD); Here’s Why (NASDAQ:GILD)
www.smarteranalyst.com - September 23 at 4:55 PM
marketrealist.com logoWhy Analysts Expect Gilead’s Revenue to Fall in 2016 and 2017 (NASDAQ:GILD)
marketrealist.com - September 23 at 4:55 PM
marketrealist.com logoPopulation Dynamics for Gilead’s HCV Products (NASDAQ:GILD)
marketrealist.com - September 23 at 4:55 PM
thecountrycaller.com logoGilead Sciences, Inc. (GILD) NASH Identified as a Hidden Asset: Gabelli (NASDAQ:GILD)
www.thecountrycaller.com - September 23 at 10:12 AM
fool.com logoThe Cheapest Stocks in Biotech (NASDAQ:GILD)
www.fool.com - September 23 at 10:12 AM
blogs.barrons.com logoGilead Sciences: Are Hepatitis C Sales Getting Better? (NASDAQ:GILD)
blogs.barrons.com - September 23 at 10:12 AM
marketrealist.com logoWhat Are Analysts’ Recommendations for Gilead Sciences? (NASDAQ:GILD)
marketrealist.com - September 23 at 10:12 AM
schaeffersresearch.com logoAnalyst Update: Weyerhaeuser Co, SeaWorld Entertainment Inc, and Gilead Sciences, Inc. (NASDAQ:GILD)
www.schaeffersresearch.com - September 22 at 5:19 PM
investopedia.com logoWill Gilead Make a Good Fit for Allergan? (GILD) (NASDAQ:GILD)
www.investopedia.com - September 22 at 5:19 PM
News IconGilead Sciences Inc. (NASDAQ:GILD) from Biotechnology – Todays Top Gains (NASDAQ:GILD)
twincountynews.com - September 22 at 5:19 PM
fool.com logoGilead Sciences Inc.'s Biggest Win in 2016 So Far (NASDAQ:GILD)
www.fool.com - September 22 at 4:55 PM
fool.com logoThe Pros and Cons of Buying Gilead Sciences Stock (NASDAQ:GILD)
www.fool.com - September 22 at 11:59 AM
News IconLeading stocks in today’s market: Gilead Sciences Inc. (NASDAQ:GILD) (NASDAQ:GILD)
twincountynews.com - September 22 at 10:46 AM
finance.yahoo.com logoGilead to Stop GS-5745 Development for Ulcerative Colitis (NASDAQ:GILD)
finance.yahoo.com - September 22 at 10:46 AM
fidaily.com logoBerenberg Initiates Coverage on Gilead Sciences, Inc. (GILD) With An Initial Rating Of “Buy” (NASDAQ:GILD)
www.fidaily.com - September 22 at 10:46 AM
smarteranalyst.com logoCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis (NASDAQ:GILD)
www.smarteranalyst.com - September 22 at 10:46 AM
bloomberg.com logoAllergan is Not Going to Buy Gilead (NASDAQ:GILD)
www.bloomberg.com - September 22 at 10:46 AM
blogs.barrons.com logoGilead Sciences: A Hidden Asset? (NASDAQ:GILD)
blogs.barrons.com - September 22 at 10:46 AM
seekingalpha.com logoM&A Action Starts To Move Gilead - Seeking Alpha (NASDAQ:GILD)
seekingalpha.com - September 21 at 5:41 PM
News IconTime To Put On The Watch List? - Gilead Sciences Inc. (NASDAQ:GILD), Galena Biopharma, Inc. (NASDAQ:GALE) - The Voice Registrar (NASDAQ:GILD)
voiceregistrar.com - September 21 at 5:41 PM
smarteranalyst.com logoMorgan Stanley Provides a Glimpse into its Global Healthcare Conference: Gilead Sciences, Inc. (GILD), Biogen Inc ... - Smarter Analyst (NASDAQ:GILD)
www.smarteranalyst.com - September 21 at 5:41 PM
investopedia.com logoPotential Acquisitions for Gilead Sciences (GILD) - Investopedia (NASDAQ:GILD)
www.investopedia.com - September 21 at 5:41 PM
publicnow.com logoGilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis (NASDAQ:GILD)
www.publicnow.com - September 21 at 5:41 PM
News IconIBM Retirement Fund Decreases Position in Gilead Sciences Inc. (GILD) (NASDAQ:GILD)
www.crcconnection.com - September 21 at 9:27 AM
schaeffersresearch.com logoOption Bulls Rush Gilead Sciences, Inc. (GILD) Amid Broader Biotech Bounce (NASDAQ:GILD)
www.schaeffersresearch.com - September 21 at 9:27 AM

Social

Gilead Sciences (NASDAQ:GILD) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff